TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03319823
Drug: Combination Medication Treatment Group
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy.
Study: NCT02449161
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01959841
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily or 400 mg once daily
Study: NCT00620724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily
Study: NCT04340544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00185250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
Study: NCT00185250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
Study: NCT00508690
Drug: kanamycin/metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Study: NCT03732508
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil intravenous infusion will be administered during the first day of treatment.
Study: NCT02312297
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: extended release tablets 135 mg
Study: NCT00598897
Drug: clarithromycin, rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
Study: NCT04156035
Drug: Placebo Pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine Placebo
Study: NCT04156035
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine Placebo
Study: NCT00001870
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03128242
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (24IU)
Study: NCT02915042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo
Study: NCT02038335
Drug: MPA/E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate and estradiol cypionate
Study: NCT01905878
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00291187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00400556
Drug: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02645461
Drug: endocannabinoid palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
Study: NCT04445688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration before bed
Study: NCT00971230
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: emtricitabine/tenofovir disoproxil fumarate
Study: NCT00971230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00636441
Drug: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
Study: NCT00006204
Drug: fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06031376
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Study: NCT03325959
Drug: Cymbalta / Lyrica treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
Study: NCT01719536
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
Study: NCT04045379
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
Study: NCT01669772
Drug: DA-9701 and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
Study: NCT01669772
Drug: Placebo and DA-9701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
Study: NCT01959139
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ug/kg on Day 1, IV over 15 minutes
Study: NCT01959139
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2, on Day 2, IV over 2 hours
Study: NCT02422485
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
Study: NCT02709811
Drug: Electrochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005773
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
Study: NCT00005773
Drug: Standard iNO therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
Study: NCT03158948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01953809
Drug: GSK1322322
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
Study: NCT01953809
Drug: EE/NE
Normalized name: EE/NETHDRONE (EQV-FEMHRT 1/5) TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
Study: NCT01953809
Drug: GSK1322322 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
Study: NCT01953809
Drug: EE/NE Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
Study: NCT00328367
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01584739
Drug: AZD8683
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
Study: NCT01584739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
Study: NCT01577628
Drug: Lipikar Balm AP
Normalized name: La Roche-Posay Lipikar Balm AP+ Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of Lipikar Balm AP starting at birth
Study: NCT00639366
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00208897
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03250832
Drug: TSR-033
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
Study: NCT03250832
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
Study: NCT03250832
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
Study: NCT00020501
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00020501
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00020501
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01761019
Drug: Taclonex Topical Suspension
Normalized name: Taclonex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical medication for psoriasis
Study: NCT03168178
Drug: Standard Antibiotic Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
Study: NCT00633529
Drug: IMO-2055
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
Study: NCT01561222
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill per day
Study: NCT01689220
Drug: SP-02L (darinaparsin for injection)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT01689220
Drug: SP-02L (darinaparsin for injection)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT02082405
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00090298
Drug: MK0653A, ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090298
Drug: Comparator: Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01843868
Drug: Standard anti-emetics in conjunction with R-CHOP
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03193788
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
Study: NCT01019980
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium
Study: NCT01019980
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen
Study: NCT01353456
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume as dexmedetomidine given
Study: NCT01454986
Drug: ALXN1007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, IV
Study: NCT00728091
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00829127
Drug: AZD8075
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
Study: NCT00829127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT03137017
Drug: Norco 5Mg-325Mg Tablet
Normalized name: Norco 5mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose in one of the four cross-over trial periods.
Study: NCT01313182
Drug: mupirocin calcium ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.
Study: NCT04628884
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose used to calculated the protamine dose
Study: NCT04628884
Drug: Dosing according residual heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
Study: NCT00285077
Drug: SR57667B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01263470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
Study: NCT00643838
Drug: Kalinox 170 bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
Study: NCT01134575
Drug: CMC-544 (Inotuzumab Ozogamycin)
Normalized name: CMC-583
Approvals — FDA: no, EMA: no, PMDA: no
Description: First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
Study: NCT02956499
Drug: APX001 single dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 single dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 single dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 single dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 single dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 multiple dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 multiple dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 multiple dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: APX001 multiple dose 4
Normalized name: TRACE-4 MULTIPLE TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956499
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04312568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Study: NCT01766180
Drug: Fruitflow-II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day for 3 months, orally
Study: NCT01766180
Drug: resVida
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day for 3 months, orally
Study: NCT03015831
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet will be given to open heart surgery patients according to randomization
Study: NCT00941031
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00941031
Drug: AIN457A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5
Study: NCT00941031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9
Study: NCT01178762
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Study: NCT02377362
Drug: GLWL-01, Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally, in 2 out of 3 periods
Study: NCT02377362
Drug: Placebo, Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally in 1 out of 3 periods
Study: NCT02377362
Drug: GLWL-01, Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
Study: NCT02377362
Drug: Placebo, Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study: NCT02377362
Drug: GLWL-01, Part C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study: NCT00094809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Study: NCT04164524
Drug: Gentamycin
Normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin 160 mg spray applied over the mesh
Study: NCT00390403
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04593836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Study: NCT01873807
Drug: IDA
Normalized name: Efidac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin: 15mg/m2/d: -8-\>-6d
Study: NCT01873807
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY:60mg/kg/d, -3d, -2d
Study: NCT02180087
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00317655
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00317655
Drug: Ginger-ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000433
Drug: Anti-Tumor Necrosis Factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00933868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
Study: NCT01253499
Drug: TRx0037
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
Study: NCT00108316
Drug: Fluoxetine (Liquid Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02172378
Drug: Placebo inhalation capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04066803
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
Study: NCT00470743
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00470743
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004898
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02046382
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Study: NCT02392156
Drug: non-Fc FVIII replacement products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
Study: NCT02392156
Drug: non-Fc FIX replacement products
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options